Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders elected all three Class III directors, with terms extending to the 2029 annual meeting.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders elected all three Class III directors, with terms extending to the 2029 annual meeting
- Shawn Cline Tomasello received 30,508,706 votes, materially below Miller-Rich and Milligan
- PwC auditor appointment ratified overwhelmingly, with 43,900,362 votes for
- Executive compensation approved on an advisory basis, with 36,065,437 votes for
- 44,038,022 shares participated, representing approximately 84% of 52,274,735 outstanding shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.